Monday, October 15, 2012
Rather than follow in the
footsteps of other foundation-backed mid-size European pharmas that have
largely concentrated on a single therapeutic area and looked to new markets for
growth, Servier has determined its path to sustainability leads through
new disease areas.
The French pharma has grown its
cardiovascular business into the fifth biggest among European pharma companies
and now wants to do the same in cancer while bolstering its diabetes,
rheumatology and neurology pipelines.